(EMAILWIRE.COM, April 15, 2020 ) We salute industry experts helping companies survive and sustain in this economic pandemic; they are working day and night to help companies take rapid-decisions by finding

+ Covid Impact on Osteoarthritis Therapeutics Market, growth/decline in product type/use cases of Osteoarthritis Therapeutics Market due to cascaded impact of Covid on Extended Ecosystem..
+ How top 50 companies in Osteoarthritis Therapeutics Market are making rapid shifts in their strategies as we speak here…
+ Outside-in view of top 50 companies client and client’s clients shifting short-term priorities

Let’s fight this crisis together. Speak to Our Analyst to analyse how COVID-19 to analyse how it is impacting your clients and your client’s clients. @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=209565994

According to the new market research report “Osteoarthritis Therapeutics Market by Anatomy (Knee, Hip), Drug Type (NSAIDs, Corticosteroids), Route of Administration (Parenteral, Topical), Distribution Channel (Hospital Pharmacies), Purchasing Pattern (Prescription Drugs) – Global Forecast to 2024″, published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).

Osteoarthritis Therapeutics Market is projected to reach USD 10.1 billion by 2024, at a CAGR of 8.1% from 2019 to 2024 Estimated at USD 6.8 billion in 2019.

The rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease are the major factors driving the growth of this industry.

Knee osteoarthritis accounted for the largest share of the Osteoarthritis Therapeutics Market, by anatomy, in 2018

Based on anatomy, Osteoarthritis Therapeutics Market segmented into knee, hip, hand, and small-joint. Knee osteoarthritis segment accounted for the largest market share in 2018. This can be primarily be attributed to a large number of patients suffering from knee osteoarthritis.

Browse in-depth TOC on “Osteoarthritis Therapeutics Market”
146 – Tables
34 – Figures
147 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209565994

By distribution channel, the hospital pharmacies segment accounted for the largest market share in 2018
Based on the distribution channel, the Osteoarthritis Therapeutics Market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment accounted for the largest market share in 2018. The high volume of patients visiting hospitals for osteoarthritis treatments and the wide range of osteoarthritis therapeutics available in these pharmacies are the major factors driving the growth of this segment.

Prescription drugs segment to grow at the highest CAGR during the forecast period

In 2018, the prescription drugs segment accounted for the largest market share and is expected to grow at the highest CAGR during the forecast period. The majority of osteoarthritis therapeutics (viscosupplementation agents and corticosteroids) are used by patients based on the prescriptions of physicians, thus, driving the growth of the segment.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=209565994

Europe was the largest regional market for osteoarthritis therapeutics in 2018

By region, the Osteoarthritis Therapeutics Market is segmented into Europe, North America, Asia Pacific, and the Rest of the World (RoW). In 2018, Europe accounted for the largest market share, followed by North America. The rising incidence & prevalence of osteoarthritis, increasing geriatric, and obese populations in the region are the major factors driving the growth of the Osteoarthritis Therapeutics Market in Europe.

Leading Companies

The prominent players operating in the Osteoarthritis Therapeutics Market include Sanofi (France), Horizon Therapeutics (Ireland), Johnson & Johnson (US), GlaxoSmithKline Plc (UK), Bayer AG (Germany), Abbott (US), Pfizer (US), Eli Lilly (US), Anika Therapeutics (US), and Flexion Therapeutics (US).